Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS sets new tech add-on payment deadline

This article was originally published in The Gray Sheet

Executive Summary

Device makers have until Nov. 20 to submit applications for fiscal year 2011 new technology add-on payments. Under the agency's Inpatient Prospective Payment System, hospitals using a new high-cost medical service or device may receive additional payment, allowing time for claims data to capture the cost of using the new technology within diagnosis related group codes, if the technology is deemed to substantially improve the diagnosis or treatment of Medicare beneficiaries. Last November, six firms applied for the add-on bonus (1"The Gray Sheet" Dec. 1, 2008). However, in the 2010 IPPS rule released July 31, only one device, Spiration's IBV Valve System for post-operative air leaks in the lung, was granted the add-on payment (2"The Gray Sheet" Aug. 10, 2009). Starting Oct. 31, CMS will pay a bonus of up to $3,427.50 for claims involving the device

You may also be interested in...



Lung Valve Device Wins Medicare Inpatient Add-On Payment

The Spiration IBV Valve System is the only product to gain a new technology add-on payment from CMS under the 2010 inpatient prospective payment system rule released July 31

Six Firms Apply For FY 2010 New Technology Add-On Payments

CMS has received four new applications for new technology add-on payments for fiscal 2010, plus two re-applications for devices that were considered last year

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel